{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:42:38Z","timestamp":1792172558414,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant ascites commonly occurs in advanced or recurrent stages of epithelial ovarian cancer during peritoneal carcinomatosis and is correlated with poor prognosis. Due to its complex composition of cellular and acellular components malignant ascites creates a unique tumor microenvironment, which mediates immunosuppression and promotes progression of disease. However, the immunosuppressive mechanisms remain poorly understood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the present study, we explored the antitumor activity of healthy donor NK and T cells directed against ovarian cancer cells in presence of malignant ascites derived from patients with advanced or recurrent peritoneal carcinomatosis. A wide range of methods was used to study the effect of ascites on NK and T cells (FACS, ELISA, EliSpot, qPCR, Live-cell and confocal microscopy, Western blot and electrolyte flux assays). The ascites components were assessed using quantitative analysis (nephelometry, potentiometry and clinical chemistry) and separation methods (dialysis, ultracentrifugal filtration and lipid depletion).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ascites rapidly inhibited NK cell degranulation, tumor lysis, cytokine secretion and calcium signaling. Similarly, target independent NK and T cell activation was impaired in ascites environment. We identified imbalanced electrolytes in ascites as crucial factors causing extensive immunosuppression of NK and T cells. Specifically, high sodium, low chloride and low potassium content significantly suppressed NK-mediated cytotoxicity. Electrolyte imbalance led to changes in transcription and protein expression of electrolyte channels and impaired NK and T cell activation. Selected inhibitors of sodium electrolyte channels restored intracellular calcium flux, conjugation, degranulation and transcript expression of signaling molecules. The levels of ascites-mediated immunosuppression and sodium\/chloride\/potassium imbalance correlated with poor patient outcome and selected molecular alterations were confirmed in immune cells from ovarian cancer patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our data suggest a novel electrolyte-based mechanism of immunosuppression in malignant ascites of patients with peritoneal carcinomatosis. We show for the first time that the immunosuppression of NK cytotoxicity in coculture assays is correlated to patient poor survival. Therapeutic application of sodium channel inhibitors may provide new means for restoring immune cell activity in ascites or similar electrolyte imbalanced environments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-023-02798-8","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T04:02:15Z","timestamp":1694145735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites"],"prefix":"10.1186","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-7963","authenticated-orcid":false,"given":"Antonio","family":"Hrvat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5554-9920","authenticated-orcid":false,"given":"Mathias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0877-6906","authenticated-orcid":false,"given":"Bernd","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4556-0541","authenticated-orcid":false,"given":"Denise","family":"Zwanziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Kimmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Volbracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-4163","authenticated-orcid":false,"given":"Sven","family":"Brandau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0781-028X","authenticated-orcid":false,"given":"Nina","family":"Mallmann-Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"issue":"3","key":"2798_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2798_CR2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","volume":"124","author":"WT Hwang","year":"2012","unstructured":"Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor -infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192\u20138.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2798_CR3","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ygyno.2021.07.003","volume":"162","author":"D Cibula","year":"2021","unstructured":"Cibula D, Rob L, Mallmann P, Knapp P, Klat J, Chovanec J, et al. Dendritic cell-based immunotherapy (DCVAC\/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): a randomized, open-label, phase 2 trial. Gynecol Oncol. 2021;162(3):652\u201360.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2798_CR4","doi-asserted-by":"crossref","first-page":"e14290","DOI":"10.1097\/MD.0000000000014290","volume":"98","author":"J Hoogstad-van Evert","year":"2019","unstructured":"Hoogstad-van Evert J, Bekkers R, Ottevanger N, Schaap N, Hobo W, Jansen JH, et al. Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study). Med (Baltim). 2019;98(5):e14290.","journal-title":"Med (Baltim)"},{"issue":"10","key":"2798_CR5","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.1990.8.10.1618","volume":"8","author":"RG Steis","year":"1990","unstructured":"Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW 2nd, Clark JW, et al. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol. 1990;8(10):1618\u201329.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2798_CR6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl499","volume":"18","author":"AA Ayantunde","year":"2007","unstructured":"Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945\u20139.","journal-title":"Ann Oncol"},{"key":"2798_CR7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-11-210","volume":"11","author":"D Lane","year":"2011","unstructured":"Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11:210.","journal-title":"BMC Cancer"},{"key":"2798_CR8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","volume":"3","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256.","journal-title":"Front Oncol"},{"issue":"3","key":"2798_CR9","doi-asserted-by":"crossref","first-page":"e13284","DOI":"10.1111\/aji.13284","volume":"84","author":"J Vazquez","year":"2020","unstructured":"Vazquez J, Chavarria M, Lopez GE, Felder MA, Kapur A, Romo Chavez A, et al. Identification of unique clusters of T, dendritic, and innate lymphoid cells in the peritoneal fluid of ovarian cancer patients. Am J Reprod Immunol. 2020;84(3):e13284.","journal-title":"Am J Reprod Immunol"},{"issue":"1","key":"2798_CR10","first-page":"161","volume":"2","author":"P Lai","year":"1996","unstructured":"Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res. 1996;2(1):161\u201373.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2798_CR11","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.4049\/jimmunol.0901226","volume":"183","author":"M Carlsten","year":"2009","unstructured":"Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, et al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol. 2009;183(8):4921\u201330.","journal-title":"J Immunol"},{"issue":"9","key":"2798_CR12","doi-asserted-by":"crossref","first-page":"e1339854","DOI":"10.1080\/2162402X.2017.1339854","volume":"6","author":"M Vyas","year":"2017","unstructured":"Vyas M, Reinartz S, Hoffmann N, Reiners KS, Lieber S, Jansen JM, et al. Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation. Oncoimmunology. 2017;6(9):e1339854.","journal-title":"Oncoimmunology"},{"issue":"9","key":"2798_CR13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/cas.12987","volume":"107","author":"S Kim","year":"2016","unstructured":"Kim S, Kim B, Song YS. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 2016;107(9):1173\u20138.","journal-title":"Cancer Sci"},{"issue":"23","key":"2798_CR14","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1158\/0008-5472.CAN-05-0623","volume":"65","author":"MB Nilsson","year":"2005","unstructured":"Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005;65(23):10794\u2013800.","journal-title":"Cancer Res"},{"issue":"3","key":"2798_CR15","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1007\/s13277-015-4198-0","volume":"37","author":"N Zhan","year":"2016","unstructured":"Zhan N, Dong WG, Wang J. The clinical significance of vascular endothelial growth factor in malignant ascites. Tumour Biol. 2016;37(3):3719\u201325.","journal-title":"Tumour Biol"},{"key":"2798_CR16","doi-asserted-by":"crossref","unstructured":"Greppi M, Tabellini G, Patrizi O, Candiani S, Decensi A, Parolini S et al. Strengthening the AntiTumor NK cell function for the treatment of Ovarian Cancer. Int J Mol Sci. 2019;20(4).","DOI":"10.3390\/ijms20040890"},{"issue":"7","key":"2798_CR17","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.0730640100","volume":"100","author":"R Castriconi","year":"2003","unstructured":"Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A. 2003;100(7):4120\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2798_CR18","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.4049\/jimmunol.180.11.7338","volume":"180","author":"M Krockenberger","year":"2008","unstructured":"Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Honig A, Hausler S, et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol. 2008;180(11):7338\u201348.","journal-title":"J Immunol"},{"issue":"32","key":"2798_CR19","doi-asserted-by":"crossref","first-page":"52045","DOI":"10.18632\/oncotarget.19090","volume":"8","author":"JB Kline","year":"2017","unstructured":"Kline JB, Kennedy RP, Albone E, Chao Q, Fernando S, McDonough JM, et al. Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-gamma receptor engagement. Oncotarget. 2017;8(32):52045\u201360.","journal-title":"Oncotarget"},{"issue":"10","key":"2798_CR20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/eji.1830111009","volume":"11","author":"SK Oh","year":"1981","unstructured":"Oh SK, Moolten FL. Purification and characterization of an immunosuppressive factor from ovarian cancer ascites fluid. Eur J Immunol. 1981;11(10):780\u20138.","journal-title":"Eur J Immunol"},{"issue":"9","key":"2798_CR21","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4049\/jimmunol.2001095","volume":"208","author":"CC Fraser","year":"2022","unstructured":"Fraser CC, Jia B, Hu G, Al Johani LI, Fritz-Klaus R, Ham JD, et al. Ovarian Cancer Ascites inhibits transcriptional activation of NK cells partly through CA125. J Immunol. 2022;208(9):2227\u201338.","journal-title":"J Immunol"},{"issue":"2","key":"2798_CR22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0021-9258(19)81445-X","volume":"242","author":"RF Chen","year":"1967","unstructured":"Chen RF. Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem. 1967;242(2):173\u201381.","journal-title":"J Biol Chem"},{"key":"2798_CR23","first-page":"2579","volume":"9","author":"GE MLVaH","year":"2008","unstructured":"MLVaH GE. Visualizing data using t-SNE. J Mach Learn Res. 2008;9:2579\u2013605.","journal-title":"J Mach Learn Res"},{"issue":"W1","key":"2798_CR24","doi-asserted-by":"crossref","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res. 2015;43(W1):W566\u201370.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2798_CR25","doi-asserted-by":"crossref","first-page":"e46858","DOI":"10.1371\/journal.pone.0046858","volume":"7","author":"A Latifi","year":"2012","unstructured":"Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS ONE. 2012;7(10):e46858.","journal-title":"PLoS ONE"},{"issue":"1","key":"2798_CR26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1600-0609.1981.tb01367.x","volume":"25","author":"K Kragballe","year":"1980","unstructured":"Kragballe K, Ellegaard J, Herlin T. Antibody-dependent monocyte-mediated cytotoxicity. The interference by platelets, immune complexes, and normal serum. Scand J Haematol. 1980;25(1):67\u201375.","journal-title":"Scand J Haematol"},{"issue":"3","key":"2798_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0090-1229(85)90046-7","volume":"36","author":"AM Dickinson","year":"1985","unstructured":"Dickinson AM, Shenton BK, Alomran AH, Donnelly PK, Proctor SJ. Inhibition of natural killing and antibody-dependent cell-mediated cytotoxicity by the plasma protease inhibitor alpha 2-macroglobulin (alpha 2\u00a0M) and alpha 2\u00a0M protease complexes. Clin Immunol Immunopathol. 1985;36(3):259\u201365.","journal-title":"Clin Immunol Immunopathol"},{"issue":"8","key":"2798_CR28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.molimm.2005.07.010","volume":"43","author":"S Preithner","year":"2006","unstructured":"Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol. 2006;43(8):1183\u201393.","journal-title":"Mol Immunol"},{"issue":"6","key":"2798_CR29","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.4049\/jimmunol.137.6.2057","volume":"137","author":"JR Medoff","year":"1986","unstructured":"Medoff JR, Clack VD, Roche JK. Characterization of an immunosuppressive factor from malignant ascites that resembles a factor induced in vitro by carcinoembryonic antigen. J Immunol. 1986;137(6):2057\u201364.","journal-title":"J Immunol"},{"issue":"8","key":"2798_CR30","first-page":"6","volume":"6","author":"SJYS Bains","year":"2016","unstructured":"Bains SJYS, Landskron J, Bjorge L, Rokkones E, Task\u00e9n K. Characterization of Immunosuppressive Properties of Malignant Ascites in Ovarian Carcinoma. Gynecology&Obstetrics (Sunnyvale). 2016;6(8):6.","journal-title":"Gynecology&Obstetrics (Sunnyvale)"},{"issue":"8","key":"2798_CR31","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8<1448::AID-CNCR12>3.0.CO;2-5","volume":"80","author":"SA Elg","year":"1997","unstructured":"Elg SA, Mayer AR, Carson LF, Twiggs LB, Hill RB, Ramakrishnan S. Alpha-1 acid glycoprotein is an immunosuppressive factor found in ascites from ovaria carcinoma. Cancer. 1997;80(8):1448\u201356.","journal-title":"Cancer"},{"issue":"6","key":"2798_CR32","first-page":"1842","volume":"40","author":"AD Hess","year":"1980","unstructured":"Hess AD, Gall SA, Dawson JR. Partial purification and characterization of a lymphocyte-inhibitory factor(s) in ascitic fluids from ovarian cancer patients. Cancer Res. 1980;40(6):1842\u201351.","journal-title":"Cancer Res"},{"issue":"12","key":"2798_CR33","doi-asserted-by":"crossref","first-page":"e15625","DOI":"10.1371\/journal.pone.0015625","volume":"5","author":"E Tran","year":"2010","unstructured":"Tran E, Nielsen JS, Wick DA, Ng AV, Johnson LD, Nesslinger NJ, et al. Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. PLoS ONE. 2010;5(12):e15625.","journal-title":"PLoS ONE"},{"key":"2798_CR34","first-page":"14","volume":"13","author":"MR Simpson-Abelson","year":"2013","unstructured":"Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O\u2019Loughlin KL, et al. Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-kappaB and NFAT signaling in tumor-associated T cells. Cancer Immun. 2013;13:14.","journal-title":"Cancer Immun"},{"key":"2798_CR35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4684-8959-0_15","volume":"146","author":"S Ladisch","year":"1982","unstructured":"Ladisch S, Ulsh L, Feig SA. Influence of monovalent cation concentrations on monocyte-mediated ADCC. Adv Exp Med Biol. 1982;146:255\u201364.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"2798_CR36","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0192-0561(85)90079-7","volume":"7","author":"T Huwyler","year":"1985","unstructured":"Huwyler T, Hirt A, Felix D, Morell A. Effect of cations and cation channel blockers on human natural killer cells. Int J Immunopharmacol. 1985;7(4):573\u20136.","journal-title":"Int J Immunopharmacol"},{"issue":"2","key":"2798_CR37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1073\/pnas.83.2.451","volume":"83","author":"L Schlichter","year":"1986","unstructured":"Schlichter L, Sidell N, Hagiwara S. Potassium channels mediate killing by human natural killer cells. Proc Natl Acad Sci U S A. 1986;83(2):451\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2798_CR38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-4827(89)90368-6","volume":"184","author":"LC Schlichter","year":"1989","unstructured":"Schlichter LC, MacCoubrey IC. Interactive effects of na and K in killing by human natural killer cells. Exp Cell Res. 1989;184(1):99\u2013108.","journal-title":"Exp Cell Res"},{"key":"2798_CR39","doi-asserted-by":"crossref","unstructured":"Zielinski CE. Regulation of T cell responses by ionic salt signals. Cells. 2021;10(9).","DOI":"10.3390\/cells10092365"},{"issue":"4","key":"2798_CR40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41577-018-0113-4","volume":"19","author":"DN Muller","year":"2019","unstructured":"Muller DN, Wilck N, Haase S, Kleinewietfeld M, Linker RA. Sodium in the microenvironment regulates immune responses and tissue homeostasis. Nat Rev Immunol. 2019;19(4):243\u201354.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2798_CR41","doi-asserted-by":"crossref","first-page":"188304","DOI":"10.1016\/j.bbcan.2019.07.001","volume":"1872","author":"TK Leslie","year":"2019","unstructured":"Leslie TK, James AD, Zaccagna F, Grist JT, Deen S, Kennerley A, et al. Sodium homeostasis in the tumour microenvironment. Biochim Biophys Acta Rev Cancer. 2019;1872(2):188304.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7621","key":"2798_CR42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature19364","volume":"537","author":"R Eil","year":"2016","unstructured":"Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature. 2016;537(7621):539\u201343.","journal-title":"Nature"},{"issue":"1","key":"2798_CR43","doi-asserted-by":"crossref","first-page":"C125","DOI":"10.1152\/ajpcell.00354.2019","volume":"318","author":"BP Luscher","year":"2020","unstructured":"Luscher BP, Vachel L, Ohana E, Muallem S. Cl(-) as a bona fide signaling ion. Am J Physiol Cell Physiol. 2020;318(1):C125\u2013C36.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"2798_CR44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1110\/ps.041079305","volume":"14","author":"R Maurus","year":"2005","unstructured":"Maurus R, Begum A, Kuo HH, Racaza A, Numao S, Andersen C, et al. Structural and mechanistic studies of chloride induced activation of human pancreatic alpha-amylase. Protein Sci. 2005;14(3):743\u201355.","journal-title":"Protein Sci"},{"issue":"6","key":"2798_CR45","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1021\/bi0205294","volume":"42","author":"JM Salhany","year":"2003","unstructured":"Salhany JM, Sloan RL, Cordes KS. The carboxyl side chain of glutamate 681 interacts with a chloride binding modifier site that allosterically modulates the dimeric conformational state of band 3 (AE1). Implications for the mechanism of anion\/proton cotransport. Biochemistry. 2003;42(6):1589\u2013602.","journal-title":"Biochemistry"},{"issue":"1","key":"2798_CR46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/imr.12438","volume":"273","author":"G Wang","year":"2016","unstructured":"Wang G. Chloride flux in phagocytes. Immunol Rev. 2016;273(1):219\u201331.","journal-title":"Immunol Rev"},{"issue":"4","key":"2798_CR47","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.4049\/jimmunol.141.4.1288","volume":"141","author":"G Prochazka","year":"1988","unstructured":"Prochazka G, Landon C, Dennert G. Transmembrane chloride flux is required for target cell lysis but not for golgi reorientation in cloned cytolytic effector cells. Golgi reorientation, N alpha-benzyloxycarbonyl-L-lysine thiobenzyl ester serine esterase release, and delivery of the lethal hit are separable events in target cell lysis. J Immunol. 1988;141(4):1288\u201394.","journal-title":"J Immunol"},{"issue":"8","key":"2798_CR48","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.4049\/jimmunol.136.8.3032","volume":"136","author":"LS Gray","year":"1986","unstructured":"Gray LS, Russell JH. Cytolytic T lymphocyte effector function requires plasma membrane chloride flux. J Immunol. 1986;136(8):3032\u20137.","journal-title":"J Immunol"},{"issue":"1","key":"2798_CR49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/157488906775245255","volume":"1","author":"F Roselli","year":"2006","unstructured":"Roselli F, Livrea P, Jirillo E. Voltage-gated sodium channel blockers as immunomodulators. Recent Pat CNS Drug Discov. 2006;1(1):83\u201391.","journal-title":"Recent Pat CNS Drug Discov"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02798-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T02:38:09Z","timestamp":1700534289000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2798"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02798-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the ethics committees of the medical faculties of the University Duisburg-Essen and of the University of Cologne. The participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have contributed and reviewed the final manuscript. All authors agreed with decision to submit with intent to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SB receives research support from Roche\/Genentech in the context of the imcore network outside of this work. All other authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}